FDA Reform Bill Could Still Face Administrative Gauntlet After Enactment
This article was originally published in The Pink Sheet Daily
Executive Summary
Implementation of new FDA drug safety authorities may not be quick or easy if lengthy rule-making is a prerequisite to action.
You may also be interested in...
REMS Not Anticipated For Every NME – FDA Official
CDER's Sandra Kweder aims to allay industry worries at Drug Industry Association meeting in Boston.
REMS Not Anticipated For Every NME – FDA Official
CDER's Sandra Kweder aims to allay industry worries at Drug Industry Association meeting in Boston.
Compromise FDA Reform Bill Passes House, Adds $225 Million In User Fees For Drug Safety
Legislation requires patient summary of clinical trial results, but only if it can be written without being promotional.